During the last 3 months, the results of two important phase-3 studies, using anti-CD38 monoclonal antibodies for the treatment of relapsed/refractory myeloma (RRMM), were published.
The first is the IKEMA study that was published in the June issue of Lancet. This is a phase 3, open-label study compared the efficacy of isatuximab plus carfilzomib-dexamethasone (IsaKd) versus carfilzomib-dexamethasone (Kd) in patients with RRMM… read more
The second is the APOLLO study that was published in the June issue of Lancet Oncology. This was a phase 3 study which compared the combination of daratumumab plus pomalidomide and dexamethasone (DaraPomDex) versus pomalidomide and dexamethasone (PomDex) alone in patients with previously treated multiple myeloma….read more
